RA
3
Pipeline Programs
3
Companies
2
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
2
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Monoclonal Antibody
2100%
+ 1 programs with unclassified modality
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
AlvotechAdalimumab
Citryll[89Zr]Zr-CIT
Clinical Trials (2)
Total enrollment: 119 patients across 2 trials
Auto-injector Real Life Handling in Patients
Start: Nov 2019Est. completion: Feb 2021107 patients
Phase 3Completed
PET-Based Imaging of Radiolabeled CIT-013
Start: Jan 2026Est. completion: Dec 202612 patients
Phase 2Recruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 119 patients
Monoclonal Antibody is the dominant modality (100% of programs)
3 companies competing in this space